There can be positive outcomes for LL in a healthcare/FDA/HHS shake up since we are a therapeutic and don't require a vaccine rollout. What will happens in the approval/oversight area is anybody's guess. But since we know this likely to happen in a few months, I felt we should discuss this. PFE board certainly has this as it's number one topic.